Istavel 100 Mg (Sitagliptin)

Product Overview

Introducing Istavel 100 Mg, a prescription antidiabetic tablet manufactured by Sun Pharmaceutical Industries Ltd. Each strip contains ten film‑coated tablets, each delivering 100 mg of sitagliptin, a well‑established dipeptidyl‑peptidase‑4 (DPP‑4) inhibitor. The product is packaged for convenient daily use and is available in three pack sizes—100, 200, and 300 tablets—allowing patients and pharmacies to select the quantity that best fits their treatment plan. Istavel is indicated for adults with type 2 diabetes mellitus who require additional glycemic control when diet and exercise alone are insufficient. The medication is distributed with a delivery window of six to fifteen days, ensuring timely access for patients across the United States. It is formulated to complement a comprehensive diabetes management program that includes nutrition counseling, physical activity, and regular monitoring of blood glucose levels.

What is Istavel 100 Mg?

Istavel 100 Mg contains sitagliptin, a selective inhibitor of dipeptidyl‑peptidase‑4 (DPP‑4). By blocking DPP‑4, sitagliptin raises levels of incretin hormones—GLP‑1 and GIP— which stimulate insulin release only when blood glucose is high and reduce inappropriate glucagon secretion. This glucose‑dependent action lowers fasting and post‑prandial glucose without causing frequent hypoglycemia. The FDA and NIH recognize sitagliptin as a safe, effective oral antidiabetic for type 2 diabetes. It is taken once daily, has a half‑life of about six hours, and is eliminated mainly by the kidneys. Its once‑daily dosing simplifies regimen adherence and supports sustained glycemic control. The drug’s pharmacokinetic profile allows steady plasma concentrations with minimal accumulation, even in patients with mild renal impairment when dose adjustments are observed.

Uses and Benefits

Clinicians prescribe Istavel 100 Mg as an add‑on therapy for adults with type 2 diabetes who have not reached target HbA1c levels with diet and exercise alone. In clinical studies, sitagliptin lowers HbA1c by about 0.5 % to 0.8 % when used alone, and greater reductions occur when combined with metformin. Its glucose‑dependent mechanism reduces the risk of hypoglycemia compared with many sulfonylureas, making it suitable for elderly patients or those with irregular eating patterns. Additionally, sitagliptin is weight‑neutral or may cause modest weight loss, which can benefit individuals with insulin resistance. Real‑world data show high patient adherence thanks to the simple once‑daily dosing. The favorable safety profile also supports its use in patients with common comorbidities such as hypertension, provided renal function is monitored.

How It Works

The action of sitagliptin centers on preserving incretin hormones released after meals. When blood glucose rises, these hormones trigger insulin release from pancreatic beta cells in a glucose‑dependent manner, while simultaneously suppressing glucagon secretion from alpha cells. This dual effect lowers both fasting and post‑prandial glucose without forcing insulin production during low‑glucose states, thereby minimizing hypoglycemia. Sitagliptin is absorbed rapidly, reaches peak concentrations within an hour, and is cleared primarily by the kidneys. With a half‑life of approximately six hours, it can be taken once daily, and steady plasma levels are achieved after about a week of consistent dosing. Because clearance is renal, patients with impaired kidney function may require dose reduction to avoid accumulation.

Dosage Guidelines

The usual starting dose of Istavel 100 Mg is one tablet taken orally once daily, with or without food. For patients with moderate renal impairment (eGFR 30‑50 mL/min/1.73 m²), the dose should be reduced to 50 mg once daily. In severe renal impairment (eGFR <30 mL/min/1.73 m²) or in those on dialysis, a 25 mg daily dose is recommended. Elderly individuals without additional risk factors may use the standard 100 mg dose, but clinicians often choose a lower dose when frailty or multiple medications are present. If a dose is missed, it should be skipped rather than doubled. Consistent daily administration helps maintain stable drug levels and optimal glycemic control. Patients should be reminded that adherence to the prescribed schedule is essential for achieving steady glycemic control.

Side Effects

Most patients tolerate Istavel 100 Mg well, but some may experience mild side effects. The most common complaints are nasopharyngitis, urinary tract infections, and mild hypoglycemia when the drug is combined with other glucose‑lowering agents. Less frequent but noteworthy events include pancreatitis, severe joint pain, and hypersensitivity reactions such as rash or angioedema. Rarely, elevations in liver enzymes have been reported; these usually return to normal after discontinuation. Although allergic symptoms—such as swelling of the face, lips, or throat—are uncommon, immediate medical attention is required if they occur. In most cases, side effects are transient and do not require medical intervention. Long‑term safety data have not shown an increased risk of major cardiovascular events, but clinicians should remain vigilant in patients with a history of heart failure or prior myocardial infarction.

Warnings and Precautions

Before starting Istavel 100 Mg, clinicians should evaluate renal function, because the drug is eliminated primarily by the kidneys and accumulation can increase exposure. Patients with known hypersensitivity to sitagliptin or any tablet component must avoid use. Caution is advised in individuals with a history of pancreatitis, as rare post‑marketing cases of pancreatic inflammation have been reported. Concomitant use of strong CYP3A4 inducers may reduce sitagliptin levels, while inhibitors may increase exposure and necessitate dose adjustment. Pregnant women should use the medication only when the benefit justifies the potential risk, and breastfeeding is generally discouraged due to limited data. Abrupt discontinuation is not required, but patients should not stop the drug without consulting their prescriber, especially if glycemic control worsens.

Patients are encouraged to discuss any concerns or questions with their healthcare provider to ensure safe and effective use of therapy.

FAQs

What is the recommended starting dose of Istavel 100 Mg?

The usual starting dose is one 100 mg tablet taken once daily, with or without food. For patients with moderate renal impairment, the dose should be reduced to 50 mg daily.

Can Istavel be used in patients with type 1 diabetes?

Istavel is approved only for type 2 diabetes. It has not been studied in type 1 diabetes, and it should not be used in this population without medical supervision.

How does Istavel differ from other DPP‑4 inhibitors?

Istavel’s once‑daily dosing and glucose‑dependent mechanism provide comparable efficacy with a low risk of hypoglycemia, and its safety profile is similar to other DPP‑4 inhibitors such as saxagliptin and linagliptin.

Are there any dietary restrictions while taking Istavel?

No specific dietary restrictions are required. Istavel can be taken with or without meals, but patients should maintain a balanced diet and regular physical activity as part of their diabetes management.

Where can I find detailed safety information for Istavel?

Comprehensive prescribing information, including side effects and contraindications, is available on the FDA label; you can review it at the U.S. Food and Drug Administration website https://www.fda.gov.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)